|
|
Abstract
Characteristics Of HIV-1 Genotyping Test After Failure With High Strengh Scheme With Nelfinavir As First Protease Inhibitor
Tupinambás U.1, Aleixo A.1, Greco D.1
Introduction: Combined antiretroviral therapy results in a sustained viral suppression and decrease of mortality and morbidity related to HIV infection. Intrinsic strength, durability and absence of cross-resistance are key factors in the selection of antiretrovirals. After the failure with nelfinavir, there are two possibilities of protease gene mutations, D30N and L90M mutation. D30N mutation does not cause cross-resistance with other protease inhibitors and decreases the viral fitness.
Methods: Two hundred and forty six HIV-1 genotyping tests performed in the Laboratory of Molecular Biology and Immunology of the Department of Infectious and Parasitic Diseases of the School of Medicine of UFMG were assessed between February 2002 and March 2004. Only the tests of patients in first failure, having nelfinavir as the first protease inhibitor (PI), preceded by double or triple therapy with non-nucleoside analogue reverse transcriptase inhibitors (nNRTI) (n=55). The interpretation of the mutations was performed using, in addition to the manufacturer’s data (Applied Biosystems, Foster City, California, USA), and the International Aids Society analysis published by its internet site and also RENAGENO algorithm were add
Results: Most of the viral strains were from subtype B (83.7%), the presence of NAM was observed in 79.5% of the tests and no INS69, complex 151, K65R and L74V mutations, which give multi-resistance to nucleoside analogue reverse transcriptase inhibitors to tenofovir and DDI, respectively, was observed. In relation to the protease gene mutations, D30N mutation was seen in 57% of the tests to L90M in 18% and the presence of wild virus in 25%.
Conclusions: These data are in accordance with the data already published in the literature, showing that the sequence therapy after failure with nelfinavir may be more change of successful as D30N mutation does not present cross-resistance with other protease inhibitors.
The 3rd IAS Conference on HIV Pathogenesis and Treatment
Abstract no.
WePe4.1C03
Suggested Citation
"TupinambásU., et al.
Characteristics Of HIV-1 Genotyping Test After Failure With High Strengh Scheme With Nelfinavir As First Protease Inhibitor .
Poster Exhibition:
The 3rd IAS Conference on HIV Pathogenesis and Treatment:
Abstract no.
WePe4.1C03"
|
|
|